JP2019108646A - 遠赤外線繊維並びにその成分及び使用 - Google Patents
遠赤外線繊維並びにその成分及び使用 Download PDFInfo
- Publication number
- JP2019108646A JP2019108646A JP2018174762A JP2018174762A JP2019108646A JP 2019108646 A JP2019108646 A JP 2019108646A JP 2018174762 A JP2018174762 A JP 2018174762A JP 2018174762 A JP2018174762 A JP 2018174762A JP 2019108646 A JP2019108646 A JP 2019108646A
- Authority
- JP
- Japan
- Prior art keywords
- far infrared
- score
- far
- fiber
- fibers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 139
- 230000005855 radiation Effects 0.000 title abstract description 21
- 239000000945 filler Substances 0.000 claims abstract description 42
- 229920000642 polymer Polymers 0.000 claims abstract description 42
- 239000004594 Masterbatch (MB) Substances 0.000 claims abstract description 35
- 230000036299 sexual function Effects 0.000 claims abstract description 28
- 239000011159 matrix material Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 14
- 239000010936 titanium Substances 0.000 claims description 14
- -1 polypropylene Polymers 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 239000004952 Polyamide Substances 0.000 claims description 11
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 11
- 229910052782 aluminium Inorganic materials 0.000 claims description 11
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 11
- 229910052732 germanium Inorganic materials 0.000 claims description 11
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- 229920002647 polyamide Polymers 0.000 claims description 11
- 229910052719 titanium Inorganic materials 0.000 claims description 11
- 239000004743 Polypropylene Substances 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 239000010949 copper Substances 0.000 claims description 10
- 239000012792 core layer Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229920001155 polypropylene Polymers 0.000 claims description 10
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 9
- 239000004800 polyvinyl chloride Substances 0.000 claims description 9
- 229910052710 silicon Inorganic materials 0.000 claims description 9
- 239000010703 silicon Substances 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 239000011651 chromium Substances 0.000 claims description 8
- 239000010410 layer Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
- 229910052788 barium Inorganic materials 0.000 claims description 7
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 229920001296 polysiloxane Polymers 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 229920002873 Polyethylenimine Polymers 0.000 claims description 6
- 239000010931 gold Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 210000004197 pelvis Anatomy 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052787 antimony Inorganic materials 0.000 claims description 5
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 229910017052 cobalt Inorganic materials 0.000 claims description 5
- 239000010941 cobalt Substances 0.000 claims description 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 5
- 229910052706 scandium Inorganic materials 0.000 claims description 5
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 4
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 239000011258 core-shell material Substances 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 abstract description 16
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 230000036760 body temperature Effects 0.000 abstract description 2
- 230000001678 irradiating effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 104
- 206010057672 Male sexual dysfunction Diseases 0.000 description 36
- 230000008859 change Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 21
- 238000000034 method Methods 0.000 description 10
- 229920001707 polybutylene terephthalate Polymers 0.000 description 8
- 206010036596 premature ejaculation Diseases 0.000 description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 description 5
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 5
- 230000009986 erectile function Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 150000001218 Thorium Chemical class 0.000 description 2
- 150000001224 Uranium Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940117229 cialis Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 229940097443 levitra Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000026455 prostate symptom Diseases 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000001730 gamma-ray spectroscopy Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- XIKYYQJBTPYKSG-UHFFFAOYSA-N nickel Chemical compound [Ni].[Ni] XIKYYQJBTPYKSG-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B17/00—Selection of special materials for underwear
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/88—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds
- D01F6/92—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B9/00—Undergarments
- A41B9/02—Drawers or underpants for men, with or without inserted crotch or seat parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/41—Devices for promoting penis erection
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/20—Compounding polymers with additives, e.g. colouring
- C08J3/22—Compounding polymers with additives, e.g. colouring using masterbatch techniques
- C08J3/226—Compounding polymers with additives, e.g. colouring using masterbatch techniques using a polymer as a carrier
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/24—Formation of filaments, threads, or the like with a hollow structure; Spinnerette packs therefor
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/28—Formation of filaments, threads, or the like while mixing different spinning solutions or melts during the spinning operation; Spinnerette packs therefor
- D01D5/30—Conjugate filaments; Spinnerette packs therefor
- D01D5/34—Core-skin structure; Spinnerette packs therefor
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
- D01F1/106—Radiation shielding agents, e.g. absorbing, reflecting agents
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/02—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D01F6/04—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/02—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D01F6/04—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins
- D01F6/06—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins from polypropylene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2467/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2467/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nursing (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Undergarments, Swaddling Clothes, Handkerchiefs Or Underwear Materials (AREA)
- Artificial Filaments (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Description
本出願は、2017年9月20日出願の台湾特許出願第106132199号の優先権を主張するものであり、本出願の全容が参照により本明細書に組み込まれる。
第1のポリマーマトリックスと、
第1のポリマーマトリックス中に分散された第1の遠赤外線充填材と、を含み、
第1の遠赤外線充填材が、以下の元素、すなわち、チタン(Ti)、ゲルマニウム(Ge)、亜鉛(Zn)、アルミニウム(Al)、及びマグネシウム(Mg)を含有し、かつ第1の遠赤外線充填材が、以下の元素、すなわち、スカンジウム(Sc)、バナジウム(V)、クロム(Cr)、コバルト(Co)、及びアンチモン(Sb)を含有しない、遠赤外線繊維を製造するためのマスターバッチを提供することである。
(1)被験者:試験中、半袖のトップ及びズボンを着用した23歳の男性
(2)実験環境:環境温度18±1℃、相対湿度50±2%
(3)試験位置:被験者の腹部、腰部及び肩
(4)試験装置:レーザードップラー血流量モニター(Moor instrument;Model No.:moorVMS−LDF)
(5)適応期間:被験者を、遠赤外線毛布を掛けずに20分間横臥させた後、被験者の血流量、血流速度及び皮膚温度を測定し、表1に記録した
(6)試験期間:被験者を、遠赤外線毛布を掛けて30分間横臥させた後、被験者の血流量、血流速度及び皮膚温度を測定し、表1に記録した。
(1)本試験の7日前以降に、経口薬物(シルデナフィル、バルデナフィル又はタダラフィル)、薬物注射、真空吸引器による陰茎海綿体の治療を受けた被験者
(2)抗高血圧薬(ドキサゾシン又は硝酸薬)、抗うつ薬、鎮静薬、ホルモン剤(抗アンドロゲン)、又は消化性潰瘍治療薬(シメチジン)を長期間服用している被験者
(3)本試験の6ヶ月前以降に、脳卒中又は脊髄損傷などの中枢系の重篤な損傷に罹患している被験者
(4)神経性要因又はホルモン要因などの非血管性要因が原因で男性性機能障害に罹患している被験者
(5)血管硬化症に罹患している被験者
(6)精神的に誘発された男性性機能障害に罹患している被験者
(7)前立腺の完全切除又は尿道前立腺部の切除を受けた被験者
(8)HIV又は肝疾患に罹患している被験者
(9)性器異常のある被験者又は性交を回避させる疾患に罹患している被験者
(10)妊娠中又は授乳中の性交パートナーを有する被験者
(11)ペイロニー病に罹患している被験者
(12)アルコール中毒又はタバコ嗜癖に罹患している被験者
(13)悪性腫瘍又は前立腺癌に罹患している被験者
(14)本試験中に手術を受ける被験者
(15)本試験中に実験手順又は評価の妨げとなり得る重篤な臨床状態又は精神状態を有する被験者。
試験前の生理学的検査の結果
試験1ヶ月後の生理学的検査の結果
試験2ヶ月後の生理学的検査の結果
試験3ヶ月後の生理学的検査の結果
Claims (17)
- 第1のポリマーマトリックスと、
前記第1のポリマーマトリックス中に分散された第1の遠赤外線充填材と、を含み、
前記第1の遠赤外線充填材が、以下の元素、すなわち、チタン(Ti)、ゲルマニウム(Ge)、亜鉛(Zn)、アルミニウム(Al)、及びマグネシウム(Mg)を含有し、かつ前記第1の遠赤外線充填材が、以下の元素、すなわち、スカンジウム(Sc)、バナジウム(V)、クロム(Cr)、コバルト(Co)、及びアンチモン(Sb)を含有しない、
遠赤外線繊維を製造するためのマスターバッチ。 - 前記第1の遠赤外線充填材が、以下の群、すなわち、ケイ素(Si)、銅(Cu)、カルシウム(Ca)、鉄(Fe)、バリウム(Ba)、カリウム(K)、ナトリウム(Na)、及びこれらの組成物から選択される元素を更に含有する、請求項1に記載のマスターバッチ。
- 前記第1の遠赤外線充填材が、以下の元素、すなわち、ケイ素、銅、カルシウム、鉄、バリウム、カリウム、及びナトリウムを更に含有する、請求項2に記載のマスターバッチ。
- 前記第1の遠赤外線充填材が、以下の群、すなわち、マンガン(Mn)、ニッケル(Ni)、ガリウム(Ga)、及びこれらの組成物から選択される元素を更に含有する、請求項1〜3のいずれか一項に記載のマスターバッチ。
- 前記マスターバッチの総重量に基づいて、チタンの量が5重量%〜40重量%の範囲であり、ゲルマニウムの量が0.01重量%〜1重量%の範囲であり、亜鉛の量が1重量%〜12重量%の範囲であり、アルミニウムの量が3重量%〜16重量%の範囲であり、マグネシウムの量が1重量%〜15重量%の範囲である、請求項1に記載のマスターバッチ。
- 前記第1のポリマーマトリックスが、以下の群、すなわち、ポリエステル、ポリウレタン(PU)、ポリ(ビニルクロライド)(PVC)、ポリプロピレン(PP)、ポリアミド(PA)、及びポリエチレンイミン(PEI)から選択される、請求項1〜4のいずれか一項に記載のマスターバッチ。
- 請求項1〜6のいずれか一項に記載のマスターバッチと、第2のポリマーと、を用いることによって製造された、遠赤外線繊維。
- 前記遠赤外線繊維がコアシェル繊維であって、コア層と、前記コア層を前記遠赤外線繊維の長軸方向に沿ってコーティングするシェル層と、を有し、前記コア層が前記マスターバッチと前記第2のポリマーとを用いることによって製造され、前記シェル層が第3のポリマーによって形成されている、請求項7に記載の遠赤外線繊維。
- 前記遠赤外線繊維の前記シェル層が、前記第3のポリマー中に分散された第2の遠赤外線充填材を更に含有し、前記第2の遠赤外線充填材が、以下の元素、すなわち、チタン、ゲルマニウム、亜鉛、アルミニウム、及びマグネシウムを含有し、かつ前記第1の遠赤外線充填材が、以下の元素、すなわち、スカンジウム、バナジウム、クロム、コバルト、及びアンチモンを含有しない、請求項8に記載の遠赤外線繊維。
- 前記第3のポリマーが、以下の群、すなわち、ポリエステル、ポリウレタン、ポリ(ビニルクロライド)、ポリプロピレン、ポリアミド、及びシリコーンから選択される、請求項7〜9のいずれか一項に記載の遠赤外線繊維。
- 前記第3のポリマーがシリコーンである、請求項10に記載の遠赤外線繊維。
- 中空繊維である、請求項7〜9のいずれか一項に記載の遠赤外線繊維。
- 請求項7〜12のいずれか一項に記載の遠赤外線繊維と、他の任意選択の繊維と、によって製造された、遠赤外線繊維の製品。
- 前記遠赤外線繊維の表面に付着した金属顆粒を更に含み、前記金属顆粒が、以下の群、すなわち、金(Au)、白金(Pt)、及びこれらの組成物から選択される金属の顆粒である、請求項13に記載の製品。
- 下着パンツである、請求項13又は14に記載の製品。
- 使用者の骨盤の前側に対応する前記下着パンツの部分における前記遠赤外線繊維の割合が、当該部分における、前記遠赤外線繊維と他の任意選択の繊維との総数に基づいて40%以上である、請求項15に記載の製品。
- 下着パンツを製造するために、請求項7〜12のいずれか一項に記載の遠赤外線繊維と、他の任意選択の繊維と、を用いること、を含み、使用者の骨盤の前側に対応する前記下着パンツの部分における前記遠赤外線繊維の割合を、当該部分における、前記遠赤外線繊維と他の任意選択の繊維との総数に基づいて40%以上とする、男性性機能の改善に有用な下着パンツの製造方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106132199 | 2017-09-20 | ||
TW106132199 | 2017-09-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019108646A true JP2019108646A (ja) | 2019-07-04 |
JP6718490B2 JP6718490B2 (ja) | 2020-07-08 |
Family
ID=65270638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017203495A Active JP6464245B1 (ja) | 2017-09-20 | 2017-10-20 | 遠赤外線繊維の男性性機能を増強するための下着 |
JP2018174762A Active JP6718490B2 (ja) | 2017-09-20 | 2018-09-19 | 遠赤外線繊維並びにその成分及び使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017203495A Active JP6464245B1 (ja) | 2017-09-20 | 2017-10-20 | 遠赤外線繊維の男性性機能を増強するための下着 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11134723B2 (ja) |
EP (1) | EP3460109B1 (ja) |
JP (2) | JP6464245B1 (ja) |
CN (1) | CN109518295A (ja) |
TW (2) | TWI673406B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190083807A1 (en) * | 2017-09-20 | 2019-03-21 | Green Energy Nano Technology Co., Ltd. | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
WO2020006693A1 (zh) * | 2018-07-04 | 2020-01-09 | 香港纺织及成衣研发中心 | 一种异形纤维在红外辐射材料及纺织品中的应用 |
CN210540422U (zh) | 2018-10-30 | 2020-05-19 | 绿能奈米科技有限公司 | 具有非动力能量层的被褥结构 |
TW202218643A (zh) * | 2020-11-05 | 2022-05-16 | 綠能奈米科技有限公司 | 複合式金屬遠紅外線醫療用貼布 |
CN115287813B (zh) * | 2022-07-08 | 2023-10-27 | 浙江棒杰数码针织品有限公司 | 一次织造成型的女性功能型生理内裤针织工艺 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6392720A (ja) * | 1986-10-03 | 1988-04-23 | Nobuhide Maeda | 遠赤外線放射性芯鞘型複合繊維 |
JPH02259110A (ja) * | 1988-12-21 | 1990-10-19 | Kuraray Co Ltd | 遠赤外線放射複合繊維及び該繊維を含有する織編物ならびに不織布 |
JPH11279830A (ja) * | 1998-03-26 | 1999-10-12 | Kuraray Co Ltd | 熱線放射性に優れる繊維 |
JP2003082524A (ja) * | 2001-07-02 | 2003-03-19 | Sota Japan Kk | 有機化学繊維、有機化学短繊維、紡績糸、布地および衣類 |
JP2006132042A (ja) * | 2004-11-08 | 2006-05-25 | Sumitomo Metal Mining Co Ltd | 近赤外線吸収繊維およびこれを用いた繊維製品 |
JP3137294U (ja) * | 2007-05-30 | 2007-11-22 | 正崇 降井 | 合成樹脂繊維糸 |
JP2008043240A (ja) * | 2006-08-14 | 2008-02-28 | Yamatoichi Shuzomoto:Kk | 梅酒梅の製造方法 |
CN101929019A (zh) * | 2009-06-18 | 2010-12-29 | 姚永利 | 温度超导智能记忆功能面料 |
JP2015518527A (ja) * | 2013-03-05 | 2015-07-02 | 毛盈▲軍▼ | 保温断熱の繊維及びその織物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960009685B1 (ko) | 1986-03-24 | 1996-07-23 | 유니버시티 오브 캘리포니아 평의원 | 자기 도우프된 중합체의 제조방법 |
JP3017125U (ja) * | 1995-02-28 | 1995-10-24 | 佳和 木田 | 健康肌着 |
JP3026650U (ja) * | 1996-01-08 | 1996-07-16 | アイビック工業株式会社 | 男性用サポ−タ− |
JP3968611B2 (ja) * | 1998-07-01 | 2007-08-29 | 東洋紡績株式会社 | 蓄熱保温材及びそれを用いた繊維製品 |
JP3349140B2 (ja) * | 2000-11-24 | 2002-11-20 | スワニー株式会社 | 遠赤外線放射性粒子含有レーヨン系繊維及びその繊維を含有した下着 |
KR100517637B1 (ko) | 2001-12-21 | 2005-09-28 | 씨제이 주식회사 | 섬수 정제 엑스 및 인삼 정제 엑스를 함께 함유하면서다른 정유 생약 성분은 함유하지 않는 조루증의 예방 및치료용 조성물 |
JP2003230779A (ja) * | 2002-02-12 | 2003-08-19 | Nissan Motor Co Ltd | クッション材およびそれからなる車両用内装材 |
JP2003342830A (ja) * | 2003-04-25 | 2003-12-03 | Sota Japan Kk | 有機化学繊維、布地及び衣類 |
JP2005126878A (ja) * | 2003-10-24 | 2005-05-19 | Taguchi Enterp:Kk | 男性用パンツ |
TW200628645A (en) | 2005-02-05 | 2006-08-16 | Zhong-Yue Cai | Artificial fiber featuring emission of far-infrared light and manufacturing method thereof |
JP2006346383A (ja) * | 2005-06-15 | 2006-12-28 | Takeshi Nakajima | カイロ収納部付きパンツ及び、該パンツと使い捨てカイロとの組み合わせ |
JP3829989B1 (ja) * | 2005-11-04 | 2006-10-04 | 三木理研工業株式会社 | レーヨン繊維の製造方法 |
JP3118478U (ja) * | 2005-11-11 | 2006-01-26 | 千晃 後藤 | 顔面補正美容バンド |
JP2007283595A (ja) * | 2006-04-14 | 2007-11-01 | Jungyoku Kin | ナノ遠赤外線エネルギーパッドの製造方法 |
KR20080107028A (ko) | 2007-06-05 | 2008-12-10 | 박명찬 | 남성용 건강 보조 기구 |
JP5122236B2 (ja) * | 2007-10-16 | 2013-01-16 | 株式会社クラレ | 遠赤外線放射繊維およびこれからなる布帛ならびにその製造方法 |
JP3139306U (ja) * | 2007-11-29 | 2008-02-07 | 株式会社Gsiクレオス | パンツ |
JP2010070885A (ja) * | 2008-09-22 | 2010-04-02 | Masayuki Saito | 尿道筋肉疲労を回復に関する下着装着体。 |
JP2011078449A (ja) * | 2009-10-02 | 2011-04-21 | Future Science:Kk | ホルミシス布 |
IT1406667B1 (it) * | 2010-09-27 | 2014-03-07 | Promogreen Com S R L | Fibre e relativi tessuti e tessuti non tessuti per il trattamento topico di disfunzioni sessuali dell'apparato genitale maschile. |
CN102302224A (zh) * | 2011-09-01 | 2012-01-04 | 成进学 | 纳米银负离子远红外防治风湿性关节炎元素织物内衣 |
CN103504885B (zh) | 2012-06-21 | 2015-09-02 | 绿能奈米科技有限公司 | 非动力式能量层的制造方法 |
US20130341819A1 (en) * | 2012-06-22 | 2013-12-26 | Green Energy Nano Technology Co., Ltd. | Manufacturing Method for Non-Powered Energy Layer |
US20140212662A1 (en) * | 2013-01-29 | 2014-07-31 | Taiwan Cheau Wei Co., Ltd. | Multi-Functional Spinning Staple Fiber Master-Batches |
US10470509B1 (en) * | 2013-03-15 | 2019-11-12 | Brannan Knott | Far infrared-based athletic apparel garment and method of use thereof |
TWI530554B (zh) | 2014-05-30 | 2016-04-21 | 吸光蓄熱母粒、其製品及其製品的製法 | |
TWI586858B (zh) | 2015-05-29 | 2017-06-11 | 台虹科技股份有限公司 | 紅外線反射纖維及紅外線反射纖維的製作方法 |
CN205585328U (zh) | 2016-04-08 | 2016-09-21 | 厦门天绅生物科技有限公司 | 一种具有保健功能的内裤 |
-
2017
- 2017-10-20 JP JP2017203495A patent/JP6464245B1/ja active Active
-
2018
- 2018-09-19 EP EP18195499.1A patent/EP3460109B1/en active Active
- 2018-09-19 CN CN201811098933.3A patent/CN109518295A/zh active Pending
- 2018-09-19 TW TW107132952A patent/TWI673406B/zh active
- 2018-09-19 JP JP2018174762A patent/JP6718490B2/ja active Active
- 2018-09-19 TW TW108131134A patent/TWI747035B/zh active
- 2018-09-19 US US16/136,141 patent/US11134723B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6392720A (ja) * | 1986-10-03 | 1988-04-23 | Nobuhide Maeda | 遠赤外線放射性芯鞘型複合繊維 |
JPH02259110A (ja) * | 1988-12-21 | 1990-10-19 | Kuraray Co Ltd | 遠赤外線放射複合繊維及び該繊維を含有する織編物ならびに不織布 |
JPH11279830A (ja) * | 1998-03-26 | 1999-10-12 | Kuraray Co Ltd | 熱線放射性に優れる繊維 |
JP2003082524A (ja) * | 2001-07-02 | 2003-03-19 | Sota Japan Kk | 有機化学繊維、有機化学短繊維、紡績糸、布地および衣類 |
JP2006132042A (ja) * | 2004-11-08 | 2006-05-25 | Sumitomo Metal Mining Co Ltd | 近赤外線吸収繊維およびこれを用いた繊維製品 |
JP2008043240A (ja) * | 2006-08-14 | 2008-02-28 | Yamatoichi Shuzomoto:Kk | 梅酒梅の製造方法 |
JP3137294U (ja) * | 2007-05-30 | 2007-11-22 | 正崇 降井 | 合成樹脂繊維糸 |
CN101929019A (zh) * | 2009-06-18 | 2010-12-29 | 姚永利 | 温度超导智能记忆功能面料 |
JP2015518527A (ja) * | 2013-03-05 | 2015-07-02 | 毛盈▲軍▼ | 保温断熱の繊維及びその織物 |
Also Published As
Publication number | Publication date |
---|---|
JP2019056196A (ja) | 2019-04-11 |
TWI673406B (zh) | 2019-10-01 |
TWI747035B (zh) | 2021-11-21 |
JP6464245B1 (ja) | 2019-02-06 |
TW201947082A (zh) | 2019-12-16 |
US11134723B2 (en) | 2021-10-05 |
EP3460109B1 (en) | 2020-09-09 |
TW201915257A (zh) | 2019-04-16 |
CN109518295A (zh) | 2019-03-26 |
EP3460109A1 (en) | 2019-03-27 |
JP6718490B2 (ja) | 2020-07-08 |
US20190082747A1 (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6718490B2 (ja) | 遠赤外線繊維並びにその成分及び使用 | |
Sydenstricker et al. | The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders | |
CN101810835A (zh) | 一种治疗紫癜的中药组合物及其制备方法 | |
Hwang et al. | TA pharmacopuncture as a primary and independent treatment for frequent sprains occurring over 9 months in a patient with needle sickness: Case report | |
CN1994439A (zh) | 一种治疗癫痫的药物 | |
Gotpagar et al. | Effect of Bosu Pilates on primary dysmenorrhea in adolescent girls | |
US11000695B2 (en) | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers | |
CN100525792C (zh) | 一种治疗脉管炎、静脉炎的中药组合物 | |
CN102813888B (zh) | 一种治疗癫痫病的中药组合物 | |
CN105943644B (zh) | 一种针对腰肌劳损的中药灸疗组合物及其制备方法和应用 | |
CN103169890B (zh) | 一种中药在社交恐怖症心理疗法中的配合应用 | |
BAnSAl et al. | Supervised Structured Exercise Program on Adolescents with Polycystic Ovary Syndrome: Two Case Reports | |
CN116370571B (zh) | 一种中药组合物、复方汤药及其制备方法及应用 | |
CN107874241A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
Ralli et al. | Post-traumatic camel-related benign paroxysmal positional vertigo | |
Krześniak et al. | Effects of circuit resistance training on the quality of life and disability of women with low back pain | |
Sahin et al. | Effects Of Two Different Aquatic Exercises Training On Cardiopulmonary Endurance And Anxiety & Depression Scores With Knee Osteoarthritis Patients: 2095 Board# 247 June 2, 2: 00 PM-3: 30 PM | |
Dasarapu et al. | Combined Body Weight, Abdominal Strengthening and Breathing Exercise for Post COVID LSCS Women | |
CN116370571A (zh) | 一种中药组合物、复方汤药及其制备方法及应用 | |
CN109260449A (zh) | 补肾壮阳的中药组合物及其应用 | |
CN103751574A (zh) | 一种用于治疗盗汗的中药组合物 | |
Smith et al. | The preliminary results of the treatment of uveitis with daraprim | |
CN102266444A (zh) | 一种治疗过敏性紫癜的药物 | |
Williams et al. | Testing The Efficacy Of An Enhanced, Individually Tailored, Theory-based, Print-delivered Exercise Promotion Intervention: 782: June 3 1: 15 PM-1: 30 PM | |
Al Shidhani et al. | Assessment of Knee Osteoarthritis in Muscat: 2094 Board# 246 June 2, 2: 00 PM-3: 30 PM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181228 |
|
AA79 | Non-delivery of priority document |
Free format text: JAPANESE INTERMEDIATE CODE: A24379 Effective date: 20190129 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200602 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200612 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6718490 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |